drugset / Trial / NCT00415636
Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for the treatment of cancer.
Timeline
- Start
- 2007-01
- Primary completion
- 2010-03
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RABUSERTIB | Small molecule | 40 mg/m2 | — |
| Subject | RABUSERTIB | Small molecule | 70 mg/m2 | — |
| Subject | RABUSERTIB | Small molecule | 105 mg/m2 | — |
| Subject | RABUSERTIB | Small molecule | 150 mg/m2 | — |
| Subject | RABUSERTIB | Small molecule | 195 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |